Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.45
    -0.16 (-2.10%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BioCryst Pharmaceuticals Inc (BCRX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect BioCryst Pharmaceuticals (BCRX) to earn $0.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $718.43M. Of 11 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.

    RatingAnalystsShare
    Strong Buy218.2%
    Buy763.6%
    Hold218.2%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 1.1% and revenue estimates rise 2.5%.

    Fiscal year ending Dec 31, 2026
    $0.87
    EPS consensus, revenue $718.43M
    Fiscal year ending Dec 31, 2027
    $0.86
    EPS consensus, revenue $736.06M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.87$0.85 to $0.882$718.43M$714.07M to $727.03M10
    Dec 31, 2027$0.86$0.81 to $0.902$736.06M$674.99M to $800.40M9

    Quarterly Estimates

    The EPS consensus rises from $0.08 for the quarter ending Dec 31, 2026 to $0.18 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.08$0.02 to $0.1712$168.16M$155.94M to $181.48M12
    Mar 31, 2027$0.18$0.17 to $0.182$166.91M$159.99M to $172.20M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 16.0% from $0.75.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.87$0.75$0.75$0.75$0.75+16.1%
    Fiscal year ending Dec 31, 2027$0.86$0.83$0.94$0.94$0.94-9.0%
    Quarter ending Mar 31, 2027$0.18$0.16$0.15$0.15$0.15+16.7%

    Frequently Asked Questions About BCRX

    What is the BCRX stock forecast?

    Consensus analyst estimates put BioCryst Pharmaceuticals's EPS at $0.87 for the fiscal year ending Dec 31, 2026, on revenue of $718.43M. The consensus rating from 11 analysts is Buy.

    How do analysts rate BCRX stock?

    Of 11 analysts covering BioCryst Pharmaceuticals, 2 rate it Strong Buy, 7 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BCRX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.87, with estimates from $0.85 to $0.88 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.86, with estimates from $0.81 to $0.90 from 2 analysts.

    What revenue do analysts expect from BioCryst Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $718.43M, with estimates from $714.07M to $727.03M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $736.06M, with estimates from $674.99M to $800.40M.

    How many analysts cover BCRX?

    11 analysts rate BioCryst Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.